Higher LE8 scores were associated with lower risks of MACE and CKD in ASCVD patients, and high LE8 achievement may attenuate risks toward non-ASCVD levels.
Abstract
Background
Patients with atherosclerotic cardiovascular disease (ASCVD) have a high risk of recurrent major adverse cardiovascular events (MACE) and chronic kidney disease (CKD). Although Life's Essential 8 (LE8) has been studied for cardiovascular outcomes in secondary prevention, systematic evaluations of its association with cardiorenal events remain lacking.
Objectives
To evaluate whether optimal cardiovascular health (CVH) was associated with lower risks of MACE and CKD in ASCVD patients.
Methods
This study included 10,253 UK Biobank participants with ASCVD, categorized into low (<50), moderate (50‒79), and high (≥80) CVH groups by LE8 score. Associations with MACE and CKD were assessed using Fine-Gray regression models, population-attributable fractions (PAF), and 1:2 propensity-matched analyses versus 16,545 non-ASCVD participants.
Results
During a median 13.3 years follow-up, 2,069 MACE and 1,290 CKD events occurred. Compared with high CVH, low CVH was associated with higher risks of MACE (subdistribution HR [sHR] 2.68, 95% CI 2.02-3.56, p <0.001) and CKD (sHR 2.34, 95% CI 1.57-3.48, p <0.001). Glucose control contributed the largest PAF to both MACE (10.5%) and CKD (15.1%), followed by smoking cessation (6.9% for MACE and 11.1% for CKD). Compared with matched non-ASCVD participants, ASCVD patients with high LE8 attenuated MACE (sHR 0.83, 95% CI 0.58-1.20; p = 0.33) and CKD (sHR 0.69, 95% CI 0.42-1.13; p = 0.14) risks.
Conclusions
Higher LE8 scores were associated with lower risks of MACE and CKD in ASCVD patients. Glucose control and smoking were key modifiable contributors. High LE8 achievement may attenuate risks toward non-ASCVD levels.
OBJECTIVE
The objective of this study was to determine whether prevalent atherosclerotic cardiovascular diseases (ASCVDs) increase the risk of amyotrophic lateral sclerosis (ALS) and whether high cardiovascular health (CVH) can offset this risk.
METHODS
We prospectively analyzed 502,279 UK Biobank participants (37-73...
Jia-Li Xie, Hao-Bo Xie, Yao-Jia Li et al.· Annals of Neurology· 0 citations
AIMS
To evaluate associations of cardiovascular health (CVH) based on Life's Essential 10 (LE10) with all-cause mortality, cardiovascular disease (CVD) and cancer mortality and incidence, and life expectancy free of CVD and cancer.
METHODS AND RESULTS
This prospective study included 110,806 UK Biobank participants (a...
Y. Dun, Li-Wen He, Randal J. Thomas et al.· European Heart Journal - Qua...· 0 citations
Objective To investigate the association between baseline total cholesterol (TC) levels and incident heart failure (HF) risk in patients with atherosclerotic cardiovascular disease (ASCVD). Methods This retrospective cohort analysis was based on the Kailuan Study, a prospective cohort initiated in Tangshan, China. A to...
Xiao-Xiao Wang, Shou-Lin Wu, Hai-Bo Gao et al.· Frontiers in Medicine· 0 citations
Advanced CKM syndrome is associated with long-term mortality outcomes including all-cause and cardiovascular death, underscoring the importance of early screening and staging of CKM syndrome to prevent disease progression and reduce mortality risk.
Lan-Lan Li, D. T. Lui, C. Fong et al.· Journal of the American Hear...· 0 citations
In T2DM, LDL-C burden and variability jointly identified patients at greater risk, especially for MI and cardiovascular mortality, especially in younger adults or longer-duration diabetes subgroups.
Dae-Jeong Koo, J. Park, Kyungdo Han et al.· Diabetes, obesity and metabo...· 0 citations
Background: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in Qatar [1,2]. The Atherosclerotic Cardiovascular Disease (ASCVD) risk estimator, which implements the Pooled Cohort Equations (PCE), is widely used to guide preventive interventions but has not been formally validated for the...
Husameldin Elhimadie, Dinas Idris· SAS Journal of Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.